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Antibodies classically bind antigens via their complementarity-
determining regions, but an alternative mode of interaction
involving V-domain framework regions has been observed for
some B cell “superantigens.” We report the crystal structure of an
antibody employing both modes of interaction simultaneously
and binding two antigen molecules. This human antibody from
an allergic individual binds to the grass pollen allergen Phl p 7.
Not only are two allergen molecules bound to each antibody frag-
ment (Fab) but also each allergen molecule is bound by two Fabs:
One epitope is recognized classically, the other in a superantigen-
like manner. A single allergen molecule thus cross-links two iden-
tical Fabs, contrary to the one-antibody–one-epitope dogma,
which dictates that a dimeric allergen at least is required for this
to occur. Allergens trigger immediate hypersensitivity reactions by
cross-linking receptor-bound IgE molecules on effector cells. We
found that monomeric Phl p 7 induced degranulation of basophils
sensitized solely with this monoclonal antibody expressed as an
IgE, demonstrating that the dual specificity has functional conse-
quences. The monomeric state of Phl p 7 and two structurally re-
lated allergens was confirmed by size-exclusion chromatography
and multiangle laser light scattering, and the results were sup-
ported by degranulation studies with the related allergens, a sec-
ond patient-derived allergen-specific antibody lacking the nonclassical
binding site, and mutagenesis of the nonclassically recognized aller-
gen epitope. The antibody dual reactivity and cross-linking mecha-
nism not only have implications for understanding allergenicity and
allergen potency but, importantly, also have broader relevance to
antigen recognition by membrane Ig and cross-linking of the
B cell receptor.
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superantigen-like recognition
The recognition of antigens by antibodies classically involvesthe complementarity-determining regions (CDRs) of the
antibody heavy-chain variable (VH) and light-chain variable
(VL) domains. However, alternative modes of antibody–antigen
interaction involving residues of the V domain framework re-
gions (FRs) have been reported: Staphylococcal Protein A and
Peptostreptococcal Protein L, for example, bind to FRs of VH
and VL domains, respectively (1, 2). These molecules are termed
“B cell superantigens” because, in polymeric form, they can
cross-link the surface Ig molecules of the B cell receptor (BCR)
independently of CDR-mediated antigen binding. This is anal-
ogous to the bacterial enterotoxins known as “T cell super-
antigens” that bind to both T cell receptor (TCR) V domains and
MHC molecules, bypassing CDR-mediated TCR recognition of
MHC-bound antigen and activating T cells in a nonspecific
manner (3). We have discovered an antibody that not only em-
ploys both “classical” (CDR-mediated) and superantigen-like
(FR-mediated) recognition of the same protein antigen but also
can bind two molecules of the antigen simultaneously.
The antibody is derived from an allergic individual (4) and
recognizes the Timothy grass-pollen allergen Phl p 7. Allergic
sensitization occurs when allergen-specific IgE molecules bind to
effector cells such as mast cells and basophils via the high-affinity
receptor FceRI. Cross-linking of receptor-bound IgE by allergen
leads to cell activation, degranulation, and release of preformed
mediators of inflammation, causing an immediate hypersensi-
tivity reaction and the characteristic manifestations of a range of
allergic conditions including allergic asthma, rhinitis (hay fever),
and food allergies (5). Phl p 7 is a highly cross-reactive “pan-
allergen” (6) whose structure has been determined in solution by
NMR and X-ray crystallography (7, 8). It is a member of the
polcalcin family and consists of two calcium-binding EF-hand
motifs in each molecule; the EF-hand is a 30-residue motif with
a characteristic structure consisting of a central metal ion-binding
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loop flanked by two helices (E and F). The NMR structure of Phl
p 7 is monomeric (7); however, the crystal structure revealed a
domain-swapped dimer (8). In the absence of calcium, confor-
mational changes occur (7, 8) which can affect recognition by IgE
(9); in the case of the antibody studied here, the subnanomolar
binding affinity for calcium-bound Phl p 7 is reduced 10,000-fold in
the absence of calcium (4).
In the crystal structure reported here, each antibody fragment
(Fab) molecule binds two monomeric Phl p 7 molecules, and
each Phl p 7 monomer bridges two Fabs. Despite its small size,
the two epitopes on Phl p 7, one recognized classically and the
other in a superantigen-like manner, do not overlap; a single
molecule of monomeric allergen could thus cross-link two
identical antibodies, as seen in the crystal structure. This is
counter to the current dogma of “one-antibody–one-epitope,”
which implies that cross-linking of identical antibodies is possible
only if the antigen (allergen) presents more than one copy of the
epitope, that is, it must be at least a dimer or have duplicated
domains. The common occurrence of dimeric allergens has been
highlighted (10–12), and two crystal structures have shown al-
lergen dimers cross-linking two identical Fabs (13, 14). If, how-
ever, the cross-linked IgE molecules are of different specificity
and recognize different epitopes, then, depending on the relative
disposition of the epitopes, a monomeric allergen could cause
cross-linking. This has been investigated recently, and cross-
linking has been demonstrated in a model system (15).
We show here in a basophil degranulation assay that mono-
meric Phl p 7 allergen can indeed cross-link identical patient-
derived monoclonal antibodies expressed as IgE, as seen in the
crystal structure, by virtue of this combination of both conven-
tional and superantigen-like recognition. Our unexpected result
may account for the potency of this and other allergens, broad-
ens our understanding of the molecular basis of allergenicity and
antigenicity in general, and has implications for designing hy-
poallergenic molecules for allergen immunotherapy. Further-
more, the dual reactivity and superantigen-like activity also
suggests a previously unanticipated mechanism for cross-linking
surface Ig molecules in the BCR, which may explain aberrant B
cell activation in autoimmune and other conditions.
Results
Phl p 7-Specific Antibodies and Their Cross-Reactivity for Related
Polcalcins. Two Phl p 7-specific antibodies, 102.1F10 and
CS09G6K, were generated from matched heavy- and light-chain
sequences by single B cell cloning from allergic individuals
(Materials and Methods) (4). Both antibodies, initially derived as
IgG4 and IgG2, respectively, were expressed as IgE antibodies to
study the cross-linking of receptor-bound IgE molecules by Phl p
7 and other polcalcin allergens. 102.1F10 was additionally
expressed as an IgG1 Fab for structural and binding studies.
There is substantial antibody cross-reactivity among the pol-
calcins (16). The affinities of 102.1F10 IgE and CS09G6K IgE
for three polcalcins, Phl p 7, Ole e 3, and Bet v 4, were de-
termined by surface plasmon resonance (SPR) analysis (SI Ap-
pendix, Fig. S1 A and B); the affinity of 102.1F10 Fab for each of
the three polcalcins was similarly measured and found to be
virtually identical to those for the IgE (SI Appendix, Fig. S1C).
The sequence similarity between Phl p 7 and Ole e 3 is 68%, and
these two allergens showed similarly high affinities for both IgE
antibodies (SI Appendix, Fig. S1D). Bet v 4, which also has 68%
sequence similarity to Phl p 7, was bound 1,000-fold more weakly
than Phl p 7 by 102.1F10 IgE and Fab, and there was no de-
tectable binding with CS09G6K IgE (SI Appendix, Fig. S1).
However, there are no structural data for complexes of any of
these other polcalcin allergens with their specific antibodies to
shed light on the precise details of the recognition of their
epitopes.
Crystal Structure of the Phl p 7/Fab Complex. We solved the struc-
ture of the complex between 102.1F10 Fab and Phl p 7 at 2.35-Å
resolution; X-ray data processing and refinement statistics are
presented in SI Appendix, Table S1. Two Fab molecules and two
monomeric Phl p 7 molecules were found in the asymmetric unit,
with each Fab binding to two Phl p 7 molecules (Fig. 1A). The
two (essentially identical) Phl p 7 molecules, which do not con-
tact one another, independently bridge the two (essentially
identical) Fabs (Fig. 1A). Each allergen molecule links the two
Fabs using two distinct interaction sites; these two different sites
can be seen for one of the Phl p 7 molecules in an orthogonal
view (Fig. 1B). The other Phl p 7 molecule similarly links the two
Fabs using an identical pair of interaction sites. These two in-
teraction sites involve distinct (nonoverlapping) epitopes on the
allergen and distinct (nonoverlapping) binding sites on the an-
tibody. Thus, each Phl p 7 molecule is bound simultaneously by
two antibody Fabs, and each Fab simultaneously binds two Phl p
7 molecules. One of these sites on the antibody is the classic
antigen-binding site involving the CDRs (Fig. 1 C and D), while
the other, unexpected site, which we term “nonclassical”, in-
volves FR residues outside the CDRs (Fig. 1 E and F). These
interaction sites are described in detail below.
Interpretable electron density was present for residues Gln1–
Thr214 in the light chains and Gln1–Lys222 in the heavy chains
of both 102.1F10 Fabs and Asp4–Met71 or –Lys72 in the two Phl
p 7 molecules. Clear density was also observed for the two cal-
cium ions in each Phl p 7 molecule. No electron density was
observed for the first three residues of either Phl p 7 molecule,
for the last six and seven C-terminal residues, or for the C-
terminal tag (V5-His tag) in either Phl p 7 molecule, although
mass spectrometry analysis on the protein from which crystals
were grown showed that the tag had been cleaved only partially.
The classical binding site of 102.1F10 Fab involves all three
CDRs of the heavy chain and CDR-L1 and CDR-L3 of the light
chain. The Fab contacts the F-helix of the N-terminal EF-hand,
the E-helix of the C-terminal EF-hand [consistent with earlier
epitope mapping in solution (16)], and residues Lys19 and
Asp48 and Asp50 and Phe54 of Ca2+-binding loops 1 and 2,
respectively (Fig. 1C). Interactions include hydrogen bonds, π–π
contacts between aromatic rings, and π–cation interactions (Fig.
1D). The interface area is ∼830 Å2, with contacts made by the
heavy chain of 102.1F10 Fab constituting over 70% of the in-
terface area, as calculated using PISA (17). CDR-H3, which has
an extended conformation toward the allergen surface, contrib-
utes most of these contacts as expected of a classical binding site.
The other, nonclassical binding site of 102.1F10 Fab involves
the light chain alone, more specifically three CDR-L2 residues
and three adjacent FR-L3 residues (Fig. 1E). The other CDRs
do not contribute to this binding interaction at all. Seven hy-
drogen bonds, a salt bridge, and cation–π interactions are formed
between the Fab and Phl p 7 at this site (Fig. 1F), which involves
the N-terminal E-helix and Ca2+-binding loop 1 of the allergen.
The interface area is ∼330 Å2, more than 30% of which is con-
tributed by three residues which involve a salt bridge between
Arg7 of Phl p 7 and Asp62 and a hydrogen bond to Thr78, both
FR-L3 residues. Asn55 in CDR-L2 also plays an important role
in this nonclassical interaction, forming two hydrogen bonds with
the allergen. Another two asparagine residues in CDR-L2, Asn53
and Asn54, form hydrogen bonds with residues Asn15 and Thr14
of the allergen, respectively.
The crystal structure thus reveals an antibody Fab binding two
antigen (allergen) molecules simultaneously and a monomeric
allergen bridging two Fabs of identical specificity (Fig. 1 A and
B). Contrary to current thinking, this implies that a mono-
meric allergen can cross-link two identical receptor-bound IgE
molecules. We therefore investigated the functional conse-
quences of this interaction for basophil degranulation by mo-
nomeric Phl p 7.
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Basophil Degranulation by Monomeric Polcalcins. Phl p 7, together
with Ole e 3 and Bet v 4, were tested for their ability as mono-
meric proteins to cause degranulation of basophils sensitized
with either 102.1F10 IgE or CS09G6K IgE. Studies on other
families of allergens, for example the profilins, have shown that
many allergens naturally dimerize. However, biophysical studies
of polcalcins Phl p 7 and Bet v 4, including NMR structure de-
terminations, have reported that these allergenic molecules are
monomeric in solution (7, 18, 19), although hydrodynamic
studies of the latter showed a minor dimeric component. In
contrast, crystallographic studies of Phl p 7 (8) and another
polcalcin Che a 3 revealed domain-swapped dimers, although
these were formed under nonphysiological conditions of low pH;
for the latter, mass spectrometry revealed a minor component of
dimer in solution (20). Phl p 7 has also been shown to undergo
temperature-dependent dimerization, but this is only reported to
occur at nonphysiological temperatures (75 °C) (21). In the
crystal structure reported here, Phl p 7 bound to 102.1F10 Fab
remains monomeric, despite the relatively high protein concen-
tration and long incubation time required for crystallization.
Size-exclusion chromatography with multiangle laser light
scattering (SEC-MALLS) was used to determine the oligomeric
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Fig. 1. The crystal structure of Phl p 7 in complex with 102.1F10 Fab reveals two monomeric allergen molecules bound independently to two identical Fabs.
The Fabs are shown in white and light gray; CDRs H1, H2, and H3 are labeled and colored magenta, orange, and blue, respectively; CDRs L1, L2, and L3 are
labeled and colored cyan, yellow, and red, respectively; Phl p 7 is shown in green; calcium ions are shown as green spheres. (A) The overall structure of the
complex: Phl p 7 (green cartoon) and Fabs (white/gray surfaces) with colored CDRs. (B) Orthogonal orientation with respect to A showing one of the Phl p
7 molecules and details (enlarged view) of its different mode of binding to each of the two identical Fabs: nonclassical interaction above and classical in-
teraction below. (C) The classical binding interaction between Phl p 7 and Fab showing involvement of the CDRs. (D) Details of the classical interaction
showing hydrogen bonds (dashed lines) with residues colored according to the code described above. (E) The nonclassical binding interaction between Phl p
7 and Fab involving light chain FR and CDR-L2 residues. (F) Details of the nonclassical interaction showing hydrogen bonds (dashed lines) with residues colored
according to the code described above. A salt bridge between Arg7 of Phl p 7 and Fab light-chain FR residue Asp62 is shown.
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state of the three allergens in solution at physiological pH (Fig.
2A). Phl p 7 was injected at a concentration of 8 mg/mL. The
mass of Phl p 7 (corresponding to the peak in the chromato-
grams, eluting at around 2 min) is 12.4 ± 1.1 kDa, in agree-
ment with the calculated value of 12.5 kDa. Bet v 4 was
injected at 0.8 mg/mL (at the lower detectable concentration
range of the SEC-MALLS system; see Materials and Methods)
and Ole e 3 at 3.6 mg/mL; the experimental values of 12.0 ±
1.4 kDa and 12.4 ± 1.0 kDa, respectively, agree with the calcu-
lated values of 13.4 kDa and 13.3 kDa. Complex formation be-
tween Phl p 7 and 102.1F10 IgE was also monitored by SEC-
MALLS (SI Appendix, Fig. S2).
The allergens were purified immediately before the basophil
degranulation assay, and the monomeric state of each was con-
firmed using SEC-MALLS (Fig. 2A). Additionally, a sample of
each protein was incubated at 37 °C until the completion of the
basophil degranulation assay for a second SEC-MALLS analysis;
these measurements revealed that all three polcalcins remained
monomeric during the time course of the degranulation assay; no
aggregates or higher-order species were detected (SI Appendix,
Fig. S3).
Basophil degranulation was assessed by β-hexosaminidase re-
lease, expressed as a percentage of that induced by cell lysis
(Materials and Methods). RBL-SX38 cells, which express human
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Fig. 2. Characterization of oligomeric state and basophil degranulation for the three polcalcin allergens. (A) Chromatograms of the RI signals for Phl p 7, Bet
v 4, and Ole e 3. The three proteins [in 25 mM Tris·HCl (pH 7.4) and 150 mM NaCl with 4 mM CaCl2] were run over a Superdex 75 5/150 column (GE Healthcare)
at a flow rate of 0.3 mL/min. The differential RI is shown in black (A.U., arbitrary units). The green lines across the protein elution volumes show the molecular
masses of the proteins, indicating a monomeric state. (B) Basophil degranulation assay showing the percentage degranulation of RBL-SX38 cells sensitized
with 102.1F10 IgE (black bars) and CS09G6K IgE (white bars) antibodies followed by stimulation with 5,000 ng/μL of Phl p 7, Bet v 4, or Ole e 3 or with assay
medium (background). Degranulation is expressed as a percentage of that induced by cell lysis. Bars represent the mean ± SEM of three independent ex-
periments. Statistical significance was determined by t test; ****P < 0.0001.
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FceRI, were sensitized with 102.1F10 or CS09G6K Phl p 7-
specific IgE and then were stimulated with 50, 500, or
5,000 ng/mL of allergen (the 5,000 ng/mL point is shown in Fig.
2B). Both Phl p 7 and Ole e 3, but not Bet v 4, induced de-
granulation of basophils sensitized with 102.1F10 IgE. While Bet
v 4 has high sequence similarity to Phl p 7 and Ole e 3, and all
three are presumably recognized classically by 102.1F10 IgE in a
similar way (indeed, all the residues involved in the nonclassical
site are conserved in all three polcalcins), Bet v 4 binding at the
classical site is substantially weaker (SI Appendix, Fig. S1A), the
likely cause of its failure to cause degranulation. None of the
three polcalcins induced degranulation of basophils sensitized
with CS09G6K IgE (Fig. 2B). (The ability of Phl p 7 to induce
basophil degranulation was tested with three Phl p 7 protein
constructs: N-terminal–tagged, C-terminal–tagged, and N-terminal
tag–cleaved. All three constructs, which are monomeric proteins,
induced degranulation of basophils sensitized with 102.1F10 IgE but
not with CS09G6K IgE. The tag therefore has no impact on the
activity of the protein).
The inability of Phl p 7 to induce degranulation of basophils
sensitized with CS09G6K IgE supports the involvement of the
nonclassical interaction with 102.1F10 IgE in basophil de-
granulation induced by monomeric Phl p 7. Both antibodies bind
Phl p 7 with high affinity (SI Appendix, Fig. S1) at overlapping
epitopes as demonstrated by competition SPR experiments, but
CS09G6K IgE expresses a Vκ rather than the Vλ light chain of
102.1F10 IgE. None of the six residues in CDR-L2 or FR-L3 of
102.1F10 IgE involved in the nonclassical interaction is present
in CS09G6K IgE.
Mutation of the Nonclassical Binding Site Abrogates Basophil
Degranulation. To test the proposed involvement of the non-
classical site in IgE cross-linking, a point mutation was made in
Phl p 7, replacing Arg7, which forms a key salt bridge with
Asp62 of FR-L3 of 102.1F10 Fab at the nonclassical binding site
(Fig. 1F), with threonine. This mutation would disrupt the salt
bridge and would be expected to severely compromise the non-
classical interaction but not affect the folding of the allergen or
its ability to be recognized by 102.1F10 IgE through the classical
binding interaction. Indeed, the Phl p 7 R7T mutant was shown
to be folded and monomeric by 1D 1H-NMR and SEC-MALLS
(Fig. 3A), respectively. Phl p 7 R7T was also shown to bind
102.1F10 IgE by SPR analysis, presumably at the classical site,
with a fourfold reduction in affinity (Kd = 6 × 10
−10 M) com-
pared with the wild-type protein (Fig. 3B); this reduced affinity is
a consequence of a slightly faster dissociation rate. Phl p 7 R7T
did not induce degranulation of RBL-SX38 cells sensitized with
102.1F10 IgE (Fig. 3C). These data are consistent with loss of the
nonclassical binding interaction, for which Arg7 is a key com-
ponent, leaving only the classical site that alone is insufficient to
induce cross-linking by monomeric Phl p 7.
Superantigen-Like Allergen Recognition. All the antibody contact
residues for both sites are presented in Table 1 together with
their genetic origin and whether they are germline encoded or
derived through somatic hypermutation. The classical interaction
site is dominated, as commonly observed, by residues generated
by junctional diversity in CDR-H3, together with somatic mu-
tations in CDR-H2 and CDR-L3. In contrast, the nonclassical
site involves six residues from CDR-L2 and the adjacent
framework FR-L3, with no involvement of the other CDRs; the
similarity to autoantigen and superantigen binding is discussed
below. Three asparagine residues in CDR-L2, Asn53, Asn54,
and Asn55, contribute critical hydrogen bonds to main-chain
atoms of the allergen, and a salt bridge and further hydrogen
bonds are contributed by spatially adjacent framework residues
Asp62, Lys68, and Thr78, as described above. Five of these six
residues are germline encoded (Vλ1–40), but Asn54 is a somatic
mutation from serine. Intriguingly, this residue position, which is
rarely involved in antigen binding, has been identified as a mu-
tational hotspot from a comprehensive comparison of sequence
data (22, 23). The S54N mutation thus contributes to the
specificity for Phl p 7 recognition in the context of a region of
germline-encoded residues that may predispose to Phl p 7 binding.
Since the Vλ1-40 gene is one of the most frequently expressed
genes of the Vλ1 family, and Asn54 is encoded in the germline
sequence of other Vλ1 family members at this position, the motif
responsible for the nonclassical interaction may be common in the
antibody repertoire.
Discussion
The structure reported here demonstrates that an antibody can
bind simultaneously to two identical protein antigens using both
classical CDR-mediated binding and nonclassical FR-mediated
binding. Furthermore, these two interactions engage epitopes on
each of the Phl p 7 allergen molecules that are nonoverlapping,
so that each Phl p 7 can be engaged simultaneously by two
identical Fabs (Fig. 1 A and B). Both observations have impli-
cations for the triggering of cellular responses through cross-
linking of antibodies, whether receptor bound or in membrane-
bound form as part of the BCR.
Contrary to the current dogma that one antibody can recog-
nize only a single epitope on an antigen (allergen), we have
demonstrated here that a monomeric allergen Phl p 7 can indeed
cross-link two identical FceRI-bound anti-Phl p 7 IgE antibodies
on a basophil and induce degranulation. We show by mutagen-
esis that this is the result of allergen recognition by the antibody
using the nonclassical as well as the classical binding sites. This
cross-linking mechanism is illustrated in Fig. 4. The antibody
used in this work was originally expressed by the allergic patient
as an IgG4, but we know that this patient also expressed Phl p 7-
specific IgE (4) and that switching from IgG4 to IgE can occur as
part of the response to allergen (24); however, we do not know
whether this exact specificity was expressed naturally by the pa-
tient as IgE. Conversion of the IgG4 antibody to an IgE con-
taining the identical matched VH and VL domains, reflecting the
natural class-switching process that occurs in vivo, does not affect
its affinity for Phl p 7, as shown previously (25) and in the
present work.
An intriguing feature of the crystal structure is the presence of
the second monomeric Phl p 7 molecule located between the two
identical Fabs (Fig. 1A). There is no contact between the two
monomers, but the way in which one monomer interacts with the
two antibodies classically and nonclassically permits the other
monomer to interact with the same two Fabs in a reciprocal
manner, that is, each antibody simultaneously binds one Phl p
7 monomer classically and the other nonclassically. Thus, if one
monomer first cross-links two IgE Fabs, a second would then
readily bind, given that the two antibody binding sites are already
disposed appropriately. The second monomer (but not behaving
as a dimer) would thus strengthen the cross-linking in a manner
akin to an avidity effect. This might be an essential feature of
this alternative mode of cross-linking and involvement of the
nonclassical site.
The dual specificity and FR-mediated binding also have im-
plications for the BCR and potential B cell superantigen-like
activity. A nonclassical mode of antibody recognition remarkably
similar to that seen here for Phl p 7 has been reported previously
in the structure of a rheumatoid factor (RF) IgM Fab fragment
bound to the autoantigen IgG-Fc (26). The RF antibody contact
residues included four that were germline encoded, one of which
was in CDR-L2, and a single somatic mutation, also in CDR-L2,
from serine to proline at position 56; this is the C-terminal residue
of CDR-L2, immediately adjacent to the framework (FR-L3).
This recognition site for the autoantigen in a location similar to
that of the Phl p 7 interaction did not overlap with the classical
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antigen-binding site either. Although the primary specificity of the
RF antibody was unknown, the structure suggested that simulta-
neous binding of the unknown antigen and the IgG-Fc auto-
antigen might be possible; this implied dual reactivity of the BCR
was proposed as a contributing factor in the generation of the RF
autoantibody (27). Furthermore, in a cryo-EM study of an anti-
hepatitis B virus antibody Fab bound to the virus capsid, classical
binding of the Fab to one antigen spike appeared to be enhanced
by simultaneous interaction through framework residues (including
the same FR-L3 region as for Phl p 7) to an adjacent spike (28).
The dual reactivity that we see for our Phl p 7-specific anti-
body, in addition to the enhanced affinity for cross-linking de-
scribed above, may also have functional implications for the
original IgG4 antibody. IgG4 antibodies perform a protective
role in allergy, blocking IgE binding to allergen epitopes (4): An
antibody with dual reactivity for two different epitopes on the
A
B
C
Fig. 3. Characterization of oligomeric state, affinity measurements, and basophil degranulation for Phl p 7 wild-type and R7T mutant. (A) Chromatograms of
the RI signals for Phl p 7 wild-type (black trace) and mutant (green trace). The two proteins [in 25 mM Tris·HCl (pH 7.4) and 150 mM NaCl with 4 mM CaCl2]
were run over a Superdex 75 5/150 column (GE Healthcare) at a flow rate of 0.3 mL/min. The lines across the protein elution volume show the molecular
masses of the Phl p 7 wild-type (black) and R7T mutant (green) proteins, indicating a monomeric state. The molecular masses as mean ± SD of three ex-
periments for Phl p 7 wild-type and mutant are 12.4 ± 1.1 kDa and 10.8 ± 1.7 kDa (elution peaks 2.02 and 2.04 mL), respectively. (B) SPR sensorgrams showing
the binding of Phl p 7 wild-type and mutant proteins to immobilized anti–lambda-biotin-102.1F10 IgE at concentrations of 5 nM (cyan), 10 nM (blue), 20 nM
(green), 40 nM (red), and 80 nM (black). The affinities of Phl p 7 wild-type and mutant are 1.7 × 10−10 M and 6 × 10−10 M, respectively. (C) Basophil de-
granulation assay showing the percentage degranulation of RBL-SX38 basophils sensitized with 102.1F10 IgE and stimulated with 5,000 ng/mL of Phl p 7 wild-
type, Phl p 7 mutant, or assay medium (background). Degranulation is expressed as a percentage of that induced by cell lysis. Bars represent the mean ± SEM
of three independent experiments. Statistically significant difference to background was determined by one-way ANOVA with Tukey’s posttest; ****P <
0.0001, nonsignificant (ns) P > 0.05.
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same allergen would, in principle, provide enhanced blocking
activity for that allergen. IgG4 antibodies, uniquely, may also
undergo Fab arm exchange (FAE) in which heavy chains of one
antibody dissociate and reassociate with the heavy chains of
another IgG4 antibody of a different specificity to generate a
bispecific molecule (29–31). An IgG4 antibody with dual speci-
ficity in a single Fab arm could thus retain this property and even
acquire an additional specificity following FAE. Such an anti-
body might have even greater blocking activity if the additional
specificity is for allergen.
B cell superantigens that bind exclusively to FR residues and
for which structural data are available include the VH-binding
Staphylococcus aureus Protein A (1) and the VL-binding Pep-
tostreptococcus magnus Protein L (2). These and other B cell
superantigens such as protein Fv (32) contain multiple binding
sites for V domains and therefore can cross-link either
membrane-bound antibody in the BCR or FceRI-bound IgE
antibodies on mast cells and basophils. In this latter regard they
have been described as superallergens (33); S. aureus entero-
toxins have also been proposed to cross-link FceRI-bound IgE
molecules using both classical and FR-mediated binding (34, 35).
The cross-linking of IgE antibodies reported here for Phl p
7 indicates that certain allergens, potentially including Ole e 3,
which also induces degranulation as a monomer, may similarly
act as superallergens by virtue of their ability to engage anti-
bodies both classically and nonclassically. This may contribute to
the potency of these allergens.
Although we were unable to measure the affinity of the FR-
mediated binding of the antibody with Phl p 7 (Materials and
Methods, SPR, and SI Appendix, Fig. S2) the relative interface
areas suggest that this is much weaker than the subnanomolar
affinity of the classical binding interaction. However, low-affinity
antibody–epitope interactions can play a critical role in triggering
mast cell or basophil activation (36); their synergy with high-
affinity interactions has been studied with antibodies of known
affinity to allergens [e.g., house dust mite Der p 2 (37)] as well as
with model allergens displaying haptens and antihapten anti-
bodies of known affinity (38). Weak interactions can contribute
in this way to IgE cross-linking and cell activation because IgE, in
contrast to IgG, with its uniquely high affinity for its Fc receptor
(FceRI), is receptor bound at the cell surface with a locally high
concentration before the appearance of the allergen. Similar
considerations will apply to membrane-bound antibodies of all
classes in their respective BCRs.
The structure reported here extends our understanding of how
an antibody can recognize an antigen, and the dual reactivity also
suggests possible mechanisms for antibody and/or BCR cross-
linking relevant to disease. With respect to allergic disease and
our understanding of allergenicity, it may also be important for
informing the design of hypoallergenic molecules for allergen im-
munotherapy (39, 40) or antibodies for passive immunization (41).
Materials and Methods
Expression and Purification of Monoclonal IgEs and IgG1 Fab. Phl p 7-specific
antibodies 102.1F10 and CS09G6K were generated by single B cell cloning
and were converted from their original IgG4 and IgG2 subclasses, re-
spectively, into IgE and, for 102.1F10, into IgG1, using polymerase in-
complete primer extension (PIPE) cloning (42). Antibody 102.1F10 was
isolated from the peripheral blood of a subject undergoing grass pollen
immunotherapy (4). Antibody CS09G6K was derived from B cells isolated
from a nasal biopsy sample from an allergic subject; nasal biopsy tissue was
dissociated by enzymatic digestion for 1 h at 37 °C with 250 μg/mL Liberase
(Roche), 50 μg/mL Hyaluronidase (Sigma), and 50 μg/mL DNase I (Roche).
Single B cells were isolated by flow cytometry, and antibody variable regions
were cloned and expressed as previously described (4). Samples were
obtained following written informed consent of participants, and all ex-
periments involving human subjects were approved by the East London and
The City research ethics committee (approval 09/H0704/67). Matched VH and
VL regions were amplified by RT-PCR from single B cell lysates. Sequences
were obtained by capillary sequencing and were cloned into expression
vectors containing corresponding human IgG1 or IgE constant regions for
recombinant expression. For the expression of IgG1 Fab, FreeStyle MAX
transfection reagent (Life Technologies) was used according to the manu-
facturer’s instructions. Suspension- and serum-free–adapted FreeStyle 293-F
cells (Life Technologies) were transfected. The Fab fragments were purified
using a HisTrap HP column according to the manufacturer’s instructions
(GE Healthcare).
Allergen Protein Expression. The DNA for full-length Phl p 7, Bet v 4, andOle e
3 was synthesized by MWG (Eurofins), codon optimized for expression in
Escherichia coli. The DNA was cloned into a pET151 vector, which includes an
N-terminal cleavable V5- and His-tag, according to the manufacturer’s in-
structions (Life Technologies), and the sequence was verified. Phl p 7 DNA
Table 1. The genetic origin of the 102.1F10 Fab contact residues in the Fab/Phl p 7 complex
Segment Contact residue Antibody region Genetic origin Binding site
VH (V1–3) S31 CDR H1 Germline Classical
Y32 CDR H1 Germline Classical
W47 CDR H2 Germline Classical
R50 CDR H2 Somatic mutation Classical
N52 CDR H2 Germline Classical
D (D3–10) F100 CDR H3 VDJ junction Classical
Y101 CDR H3 VDJ junction Classical
S103 CDR H3 VDJ junction Classical
S104 CDR H3 VDJ junction Classical
G105 CDR H3 VDJ junction Classical
JH (JH4) — — —
VL(Vλ1–40) Y33 CDR L1 Germline Classical
N53 CDR L2 Germline Nonclassical
N54 CDR L2 Somatic mutation Nonclassical
N55 CDR L2 Germline Nonclassical
D62 FR L3 Germline Nonclassical
K68 FR L3 Germline Nonclassical
T78 FR L3 Germline Nonclassical
F93 CDR L3 Somatic mutation Classical
W100 CDR L3 Germline Classical
JL (Jλ4) — — —
H, heavy chain; L, light chain; VDJ, variable diversity joining.
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was also cloned into a pET101 vector, which includes a C-terminal non-
cleavable V5- and His-tag. For expression, the plasmid was transformed into
BL21 star DE3 (Life Technologies) and was plated on ampicillin overnight.
The colonies were used to inoculate a 5-mL starter culture in Luria broth,
with ampicillin; this culture was grown for 6 h and then was used to in-
oculate 250 mL ZYP-5052 autoinduction medium overnight (43). The bac-
teria were harvested by centrifugation at 4,000 × g and then were lysed
using BugBuster (Merck Millipore) according to the manufacturer’s instruc-
tions. The soluble fraction had imidazole added to a final concentration of
10 mM and then was passed over a 1-mL HisTrap column (GE Healthcare)
using an AKTA prime chromatography system (GE Healthcare Life Sciences)
and was washed with Tris-buffered saline (TBS) buffer [25 mM Tris·HCl (pH
7.4), 300 mM NaCl, 4 mM CaCl2] containing 10 mM imidazole. The protein
was eluted using TBS (as above) containing 500 mM imidazole. A fraction of
the His-V5-Phl p 7 protein was set for 8 h dialysis at 4 °C in a buffer con-
taining 25 mM Tris·HCl (pH 7.4), 150 mM NaCl, 4 mM CaCl2, 20 mM imid-
azole, 1 mM DTT, and tobacco etch virus (TEV) protease (0.2 mg) for the
cleavage of the His-tag. The reaction mixture was then applied to a HisTrap
column (GE Healthcare) to remove the cleaved tag. The concentrations of
His-V5-Phl p 7, His-V5-Bet v 4, and His-V5-Ole e 3 were determined with a DS-
11 spectrophotometer (DeNovix). Phl p 7-V5-His and Phl p 7 (without the
tag) contain no tyrosine or tryptophan residues and thus absorb poorly at
280 nm; therefore conventional spectroscopic detection was not useful.
Fractions containing protein were identified by SDS gel electrophoresis,
pooled, concentrated, and run over a Superdex 75 10/300 column (GE
Healthcare) in TBS with 4 mM CaCl2 and 0.1% sodium azide, monitoring the
wavelength at 208 nm for the peptide backbone and at 257 nm for phe-
nylalanine. Fractions from the peak corresponding to the allergen were
pooled and concentrated for experimental use.
SPR. All experiments were carried out on a Biacore T200 instrument (GE
Healthcare) at 25 °C. To measure the affinity of Phl p 7 and other cross-
reactive allergens to 102.1F10 IgE, CaptureSelect biotinylated anti-lambda
conjugate (Thermo Fisher Scientific) was immobilized onto a streptavidin
chip (GE Healthcare). Then 2 nM 102.1F10 IgE was injected at 5 μL/min, and
∼500 resonance units of the antibody were captured onto the anti-lambda
surface. For CS09G6K IgE, CaptureSelect biotinylated anti-kappa conjugate
(Thermo Fisher Scientific) was used under identical conditions. Different
effector cell
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Fig. 4. Schematic mechanism of the cross-linking of two identical receptor-bound IgE antibodies by monomeric Phl p 7 on the cell surface. High-affinity
receptor (cyan) and IgE (gray and magenta for heavy and light chain, respectively) complexes are cross-linked by allergen (green). The monomeric allergen
binds to two distinct paratopes on IgE. (Left) The classical binding site involving all CDRs except CDR-L2 of the antibody. (Right) The other nonclassical,
superantigen-like binding site involves only CDR-L2 and FR-L3 residues of the VL domain of the antibody. The Insets show the molecular details of the in-
teraction between monomeric Phl p 7 (green cartoon) and the two identical Phl p 7-specific Fabs (white). CDRs of the heavy chain H1, H2, and H3 are labeled
and colored magenta, orange, and blue, respectively; CDRs of the light chain L1, L2, and L3 are labeled and presented in cyan, yellow, and red, respectively.
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concentrations of allergens were prepared by a twofold serial dilution in TBS
buffer [25 mM Tris·HCl (pH 7.4), 150 mM NaCl, 4 mM CaCl2, 0.005% surfac-
tant P20]: Phl p 7 (twofold dilution series 0.35–500 nM), Ole e 3 (twofold
dilution series 0.35–500 nM), Bet v 4 (twofold dilution series 4–1,600 nM).
The samples were injected at 20 μL/min with an association phase of 180 s
followed by a 10-min dissociation phase.
Purified 102.1F10 Fab was immobilized on a CM5 sensor chip by amine
coupling. Allergens were injected over the surface for 240 s at a flow rate of
20 μL/min followed by a dissociation time of 900 s at a flow rate of 20 μL/min.
Regeneration of the sensor surface was performed with a 60-s injection of
10 mM glycine-HCl (pH 2.5). These binding experiments were run in HBS
buffer [10 mM Hepes (pH 7.4) 150 mM NaCl, 4 mM CaCl2, and 0.005% sur-
factant P20]. Biacore T200 Evaluation software was used to analyze and
present the data. Sensorgrams were all well fitted to a 1:1 stoichiometry
model, including those for Phl p 7 binding to antibody 102.1F10 (SI Ap-
pendix, Fig. S4), which indicates that the affinity of the nonclassical in-
teraction with this allergen is considerably weaker than that of the
subnanomolar classical binding interaction and does not contribute to the
sensorgram at the concentrations used here.
SEC-MALLS. Protein samples were first run over a Superdex 75 10/300 column
(GE Healthcare), and the peak corresponding to the monomeric allergen was
then used for SEC-MALLS analysis and the basophil degranulation assays. Be-
fore SEC-MALLS analysis the samples were dialyzed against 25 mM Tris·HCl and
150 mM NaCl TBS (pH 7.4) with 4 mM CaCl2. For the SEC-MALLS analysis,
protein samples were injected onto a Superdex 75 5/150 column (GE Health-
care) connected to an 1100 Series HPLC (Agilent Technologies). MALLS device
detectors were normalized using TBS buffer (as above) supplemented with
4 mM CaCl2 (pH 7.4) as the isotropic scattering agent; the flow rate was
0.3 mL/min. Each run was performed with 0.8 mg/mL of Bet v 4, 5 mg/mL of
Ole e 3, 10 mg/mL of Phl p 7 wild-type, and 3 mg/mL of Phl p 7 mutant at
37 °C; the sample volume was 60 μL. Light-scattering and refractive index (RI)
changes were monitored using a Viscotek SECMALS 20 (Malvern Instru-
ments) multiangle light-scattering detector and a Viscotek VE3580 (Malvern
Instruments) RI detector. Molecular weight and mass calculations were
performed with the OMNISEC 5.02 software (Malvern Instruments). For the
analysis of Phl p 7 complexes with 102.1F10 IgE (SI Appendix, Fig. S2),
a Superdex 200 Increase 5/150 column (GE Healthcare) was used; buffer
conditions were as described above. Light-scattering and RI changes
were monitored using a miniDAWN (Wyatt Technology) multiangle light-
scattering detector and an Optilab DSP (Wyatt Technology) RI detector.
Molecular weight and mass calculations were performed with Astra 4.90
software (Wyatt Technology).
Basophil Degranulation Assay. RBL-SX38 cells, which express the human tet-
rameric form of FceRI (44), were routinely cultured in RPMI medium sup-
plemented with 10% FCS, 2 mM L-glutamine, 10 U penicillin/streptomycin,
and 50 μg/mL Geneticin (all from Invitrogen) at 37 °C and 5% CO2 in hu-
midified air. RBL-SX38 cells were seeded at 1 × 104 cells per well in a 96-well
plate in RPMI medium supplemented with 10% FCS, 2 mM L-glutamine, and
10 U penicillin/streptomycin and were incubated at 37 °C, 5% CO2 in hu-
midified air overnight. Following washing with HBSS (Invitrogen)/1% BSA
(Sigma-Aldrich), cells were stimulated overnight by incubation with 200 ng/mL
IgE diluted in HBSS/1% BSA at 37 °C and 5% CO2 in humidified air. Cross-
linking of IgE-bound FceRI was carried out by incubation with 50, 500, or
5,000 ng/mL allergen diluted in HBSS/1% BSA for 1 h at 37 °C and 5% CO2 in
humidified air. Supernatants were harvested for analysis. HBSS/1% BSA,
polyclonal rabbit anti-human IgE (Dako), and HBSS/1% BSA/0.5% Triton X-100
(Sigma-Aldrich) were used as controls for background, crosslinking, and
maximum degranulation, respectively. β-Hexosaminidase release was mea-
sured using 4-methylumbelliferyl N-acetyl-β-D-glucosaminide substrate (Sigma-
Aldrich) as previously described (45), and degranulation was expressed as a
percentage of the maximum degranulation induced by HBSS/1% BSA/0.5%
Triton X-100.
Crystallization. Sitting-drop vapor diffusion crystallization screens were set up
for the 102.1F10 Fab/Phl p 7 complex using a protein concentration of
3.7 mg/mL in a buffer comprising 25 mM Tris·HCl (pH 7.5), 20 mM NaCl,
4 mM CaCl2, and 0.01% sodium azide. Crystals were grown at 18 °C using
100 μL reservoir solution comprising 0.1 M 2-(N-morpholino) ethanesulfonic
acid (pH 6.5), 15% (wt/vol) PEG 6000, and 10% (vol/vol) 2-methyl-2,4-
pentanediol. Crystals appeared after 5 d and were flash-cooled in liquid
nitrogen using the reservoir supplemented with an additional 5% (vol/vol)
2-methyl-2,4-pentanediol as cryoprotectant.
Crystallographic Data Collection and Processing. Complete datasets were
collected at beamline I02, Diamond Light Source (Harwell, United Kingdom).
XDS (46) in Xia2 (47) and aimless (48) from the CCP4 Suite (49) were used to
integrate and merge the data to a resolution of 2.35 Å. The crystal grew in
space group P21, with unit cell dimensions a = 52.7 Å, b = 178.7 Å, c = 66.1 Å,
and β = 94.8°. The structure was solved by molecular replacement with
Phaser (50). To generate the 102.1F10 Fab search model, the BALBES data-
base (51) was used to find the VL and Cλ domains from 3H42 and the
CH1 and VH domains from 1RZF, from which the CDRs were removed
manually. Iterative model building was performed in Coot (52) and re-
finement with PHENIX (53). Data processing and refinement statistics are
summarized in SI Appendix, Table S1; the quality of the model was assessed
with MolProbity (54). Structural figures were drawn using PyMOL (55). Co-
ordinates and structure factors have been deposited in the Protein Data
Bank under ID code 5OTJ.
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